Abstract 2112P
Background
The WHO (World Health Organization) defines elderly as individuals aged 60 years or older in developing countries. It is known that due to sociodemographic changes such as increased life expectancy, there was an increase in the prevalence of cancer diagnosis in this population subgroup. Associated with the fact that historically these individuals are underrepresented in the main oncological clinical studies, the challenge of a better way of evaluating these patients, who inherently have different physiological characteristics, arises. In this context, the Comprehensive Geriatric Assessment (GGA) is consolidated as an adequate application tool. This study aims to evaluate, based on the domains of the CGA, elderly patients with malignant neoplasm of the digestive tract who will start chemotherapy treatment and associate it with the tolerability of the treatment after 3 months.
Methods
This prospective study included patients with neoplasia of the digestive tract: esophagus, stomach, pancreas, biliary tract, colon and rectum, evaluated at baseline and after 3 months of chemotherapy. Patients aged 60 years or older were selected. The CGA was applied at the beginning of the treatment. Treatment tolerability was defined in this study by toxicity and maintenance or not of the chosen treatment at the end of 3 months. The data were registered in Excel and subsequently imported into IBM-SPSS Statistics version 28 for comparative analysis between groups. This study was approved by the ethics committee (CAAE:30127320.0.0000.5505). All patients signed a Term of Free and Informed Consent before inclusion.
Results
50 patients (median age: 68), colorectal (42%). Stage II: 7 patients, III:18, IV: 25.Correlated with toxicity: IADL (Instrumental Activities of Daily Living) and nutritional status. Dependent for IADL developed more G3 toxicity (p= 0.048) and were unable to continue treatment: the Lawton scale (p=0.020) ;Pfeffer questionnaire (p=0.024).Malnourished developed more G3 toxicity (p=0.003) and suspended/modified treatment (p=0.002).
Conclusions
The evaluation of functionality and nutrition domains were associated with toxicity and maintenance of treatment after 3 months.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06